Veterinary Medicines

HIPRABOVIS-4 ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ

Authorised
  • Infectious Bovine rhinotracheitis virus, strain LA, Inactivated
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
  • Bovine respiratory syncytial virus, strain Lym-56, Live
Download as PDF

Product identification

Medicine name:
HIPRABOVIS-4 ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ
Active substance:
  • Infectious Bovine rhinotracheitis virus, strain LA, Inactivated
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
  • Bovine respiratory syncytial virus, strain Lym-56, Live
Target species:
  • Cattle
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Infectious Bovine rhinotracheitis virus, strain LA, Inactivated
    10000000.00
    tissue culture infective dose 50
    /
    1.35
    millilitre(s)
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
    1000000.00
    tissue culture infective dose 50
    /
    0.75
    millilitre(s)
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
    1000000.00
    tissue culture infective dose 50
    /
    0.60
    millilitre(s)
  • Bovine respiratory syncytial virus, strain Lym-56, Live
    100000.00
    tissue culture infective dose 50
    /
    1.00
    Tablet
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        21
        day
  • Subcutaneous use
    • Cattle
      • Meat and offal
        21
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AH
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone)
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 35067/18-10-1999/K-0114301
Date of authorisation status change:
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."